Since the introduction of new anthracycline derivatives and anthrachi none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig nancies. A special symposium was therefore held during the congress of the German Society of Hermatology and Oncology in Hannover in October 1989 to provide an up-to-date overv.iew. Leading experts from the United States, Sweden, and Germany reported on the results being obtained with aclacinomycin A, alone or combined with other agents, in patients with acute leukemias and myelodysplastic syndromes. This book is based on their contributions. As regards single-agent treatment, aclacinomycin A in myelodys plastic syndromes is dealt with, as well as its application in older patients with acute myeloid leukemia. Four contributions are devoted to the use of aclacinomycin A in combination with conventional or intermediate dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable update on the current status of aclacinomycin A as used by experts in the treatment of he matologic malignancies.

Aclarubicin in Single Agent and Combined Chemotherapy of Adult Acute Myeloid Leukemia

Low-Dose Aclacinomycin and Intermediate-Dose Cytosine - Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia
Aclarubicin Plus Cytosine Arabinoside Versus Daunorubicin Plus Cytosine Arabinoside in De Novo Acute Myelocytic Leukemia: A Danish National Trial
Fractionated Aclacinomycin in Combination with Cytosine Arabinoside and Etoposide for Remission Induction in Adult Acute Myeloid Leukemia
Aclarubicin in the Treatment of Refractory Acute Leukemias
Aclacinomycin A/Etoposide Combination Therapy for Advanced Relapsed Acute Myeloid Leukemia: Results of a Pilot Study of the Arbeitsgemeinschaft Internistische Onkologie
Low-Dose Aclacinomycin A in Myelodysplastic Syndromes and Subsequent Acute Myelogenous Leukemia: A Phase II Study.